Rasilez

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Aliskiren hemifumarate 331.5mg equivalent to 300 mg aliskiren;  ;  

Verfügbar ab:

Novartis New Zealand Ltd

INN (Internationale Bezeichnung):

Aliskiren hemifumarate 331.5 mg (= 300 mg aliskiren)

Dosierung:

300 mg

Darreichungsform:

Film coated tablet

Zusammensetzung:

Active: Aliskiren hemifumarate 331.5mg equivalent to 300 mg aliskiren     Excipient: Colloidal silicon dioxide Crospovidone Basic coating premix white Basic coating premix red Basic coating premix black Magnesium stearate Microcrystalline cellulose Povidone

Einheiten im Paket:

Blister pack, PA/Al/PVC, 7 tablets

Klasse:

Prescription

Verschreibungstyp:

Prescription

Hergestellt von:

Novartis Grimsby Limited

Anwendungsgebiete:

Rasilez is indicated for the treatment of hypertension.

Produktbesonderheiten:

Package - Contents - Shelf Life: Blister pack, PA/Al/PVC - 7 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 14 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 28 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 30 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 50 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 56 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 84 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 90 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 98 tablets - 24 months from date of manufacture stored at or below 30°C - Blister pack, PA/Al/PVC - 280 tablets - 24 months from date of manufacture stored at or below 30°C

Berechtigungsdatum:

2006-10-13